Syndeio Biosciences (derived from Ancient Greek and meaning to connect) is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders. The company's proprietary Boost™ Synapse Pharmacology Platform combines electrophysiology, behavior, and human neuronal network assays to predict clinical outcomes with unprecedented accuracy. Originally developed at Stanford and now expanded through proprietary IP and data systems, Boost™ de-risks new synaptic agents and guides effective treatment strategy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/06/25 | $90,000,000 |
AbbVie Ventures Catalio Capital Eli Lilly and Company Innoviva Luson Bioventures Palo Santo Investors Tenmile | undisclosed |
